Quarterly report pursuant to Section 13 or 15(d)

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)

v3.5.0.2
2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)
 3 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2016
Sep. 30, 2015
Sep. 30, 2016
Sep. 30, 2015
Dec. 31, 2015
Increase in cost of goods sold due to reclassification   $ 111,391   $ 235,213  
Decrease in selling, general and administrative expenses due to reclassifcation   111,391   235,213  
Net loss $ (1,900,736) (989,549) $ (5,660,755) (5,641,426)  
Cash flows from operations     (1,429,277) (2,924,177)  
Cash equivalents 0   0   $ 0
Cash in excess of FDIC limits 547,221   547,221    
Notes receivable 540,351   540,351   617,681
Allowance for doubtful accounts 100,000   100,000   100,000
Shipping and handling 115,990 111,391 313,498 235,213  
Allowance for customer returns 0 0 0 0  
Inventory 13,206,088   13,206,088   $ 14,133,920
Depreciation expense 48,977 47,678 146,692 141,222  
Research and development expense 396,238 228,822 $ 879,598 $ 972,844  
Options [Member]          
Potentially dilutive shares outstanding     11,924,776 9,258,888  
Warrants [Member]          
Potentially dilutive shares outstanding     2,100,000    
Common Stock [Member] | Performance Based Options [Member]          
Potentially dilutive shares outstanding     11,000,000    
Common Stock [Member] | Contingent Consideration [Member]          
Potentially dilutive shares outstanding     19,500,000    
Accounts Receivable [Member] | One Customer [Member]          
Concentration risk percentage     60.50%    
Accounts Receivable [Member] | Two Customers [Member]          
Concentration risk percentage         83.00%
Germany and The Netherlands [Member]          
Inventory 1,326,911   $ 1,326,911    
Pharmaceutical Segment [Member]          
Capital required over next 12 months     1,500,000    
Consumer Products Segment [Member]          
Research and development expense 292,738 228,822 658,817 $ 972,844  
Specialty Pharmaceutical Segment [Member]          
Research and development expense $ 103,500 $ 0 $ 220,781 $ 0